Novo Nordisk reported a rapid initial uptake for its oral Wegovy weight‑loss pill, with prescriptions ramping up roughly 500% in the product’s second week on the market. Analysts flagged strong early demand and rising prescription counts as evidence of patient and prescriber interest in an oral GLP‑1 alternative. The early surge may influence payer coverage discussions and supply planning, as stakeholders assess real‑world uptake beyond clinic trial settings. Novo’s results will be watched closely by competitors and investors evaluating the commercial trajectory of small‑molecule GLP‑1 candidates and their impact on obesity treatment markets.